Characterization of ERK Docking Domain Inhibitors that Induce Apoptosis by Targeting Rsk-1 and Caspase-9Sarice R Boston, Paul Shapiro, U. Deva Priyakumar et al.|BMC Cancer|2011Cited by 44
DESTINY-Breast07: Dose-expansion interim analysis of T-DXd monotherapy and T-DXd + pertuzumab in patients with previously untreated HER2+ mBC.Fabrice André, Komal Jhaveri, Erika Hamilton et al.|Journal of Clinical Oncology|2024Cited by 32
Abstract PD18-11: Dose-Expansion Study of Trastuzumab Deruxtecan as Monotherapy or Combined With Pertuzumab in Patients With Metastatic Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Breast Cancer in DESTINY-Breast07 (DB-07)Erika Hamilton, Fabrice André, Komal Jhaveri et al.|Cancer Research|2023Cited by 5